120 related articles for article (PubMed ID: 33955714)
1. Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology.
Sanghavi K; Vuppala P; Ivaturi V; Hamuro L; Roy A; Suryawanshi S
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):748-759. PubMed ID: 33955714
[TBL] [Abstract][Full Text] [Related]
2. Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma.
Du S; Zhao Y; Hu Z; Liu S; Roy A; Shen J; Zhu L; Hamuro L
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):168-179. PubMed ID: 37873561
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
Leroy M; Desmedt E; Deramoudt L; Vasseur M; Odou P; Béhal H; Décaudin B; Mortier L; Simon N
Melanoma Res; 2024 Jun; 34(3):258-264. PubMed ID: 38489575
[TBL] [Abstract][Full Text] [Related]
5. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
Puszkiel A; Bianconi G; Pasquiers B; Balakirouchenane D; Arrondeau J; Boudou-Rouquette P; Bretagne MC; Salem JE; Declèves X; Vidal M; Kramkimel N; Guegan S; Aractingi S; Huillard O; Alexandre J; Wislez M; Goldwasser F; Blanchet B
Br J Cancer; 2024 May; 130(11):1866-1874. PubMed ID: 38532102
[TBL] [Abstract][Full Text] [Related]
6. Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors.
Zhao Y; Sanghavi K; Roy A; Murthy B; Bello A; Aras U; Vezina H
Clin Pharmacol Ther; 2024 Mar; 115(3):488-497. PubMed ID: 38115195
[TBL] [Abstract][Full Text] [Related]
7. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis.
Xu Y; Hezam K; Ali MG; Wang Y; Zhang J
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):386-394. PubMed ID: 34014122
[No Abstract] [Full Text] [Related]
9. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Rosenberg JE; Ballman KA; Halabi S; Atherton PJ; Mortazavi A; Sweeney C; Stadler WM; Teply BA; Picus J; Tagawa ST; Katragadda S; Vaena D; Misleh J; Hoimes C; Plimack ER; Flaig TW; Dreicer R; Bajorin D; Hahn O; Small EJ; Morris MJ
J Clin Oncol; 2021 Aug; 39(22):2486-2496. PubMed ID: 33989025
[TBL] [Abstract][Full Text] [Related]
10. Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
Debieuvre D; Juergens RA; Asselain B; Audigier-Valette C; Auliac JB; Barlesi F; Benoit N; Bombaron P; Butts CA; Dixmier A; Gröschel A; Gutz S; Labbé C; Moro-Sibilot D; Pérol M; Raspaud C; Schumann C; Juarez-Garcia A; Lakhdari K; Pettersson F; Penrod JR; Reynaud D; Waldenberger D; Allan V; Sebastian M
Lung Cancer; 2021 Jul; 157():40-47. PubMed ID: 33980420
[TBL] [Abstract][Full Text] [Related]
11. Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis.
Quhal F; Mori K; Remzi M; Fajkovic H; Shariat SF; Schmidinger M
Curr Opin Urol; 2021 Jul; 31(4):332-339. PubMed ID: 33965978
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.
Skarbnik AP; Donato ML; Feinman R; Rowley SD; Vesole DH; Goy AH; Munshi PN; Feldman T; Leslie LA; Biran N; Nyirenda T; Fields PA; Descalzi-Montoya D; Zenreich J; Korngold R; Pecora AL
Transplant Cell Ther; 2021 May; 27(5):391-403. PubMed ID: 33965177
[TBL] [Abstract][Full Text] [Related]
13. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA; Kang N; Lee SJ; Hodi FS; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963015
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
15. Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood.
Rad Pour S; Pico de Coaña Y; Demorentin XM; Melief J; Thimma M; Wolodarski M; Gomez-Cabrero D; Hansson J; Kiessling R; Tegner J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963011
[TBL] [Abstract][Full Text] [Related]
16. Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy.
Rubino R; Marini A; Roviello G; Presotto EM; Desideri I; Ciardetti I; Brugia M; Pimpinelli N; Antonuzzo L; Mini E; Livi L; Maggi M; Peri A
Endocrine; 2021 Oct; 74(1):172-179. PubMed ID: 34036513
[TBL] [Abstract][Full Text] [Related]
17. Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry.
Jochems A; Bastiaannet E; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; van den Eertwegh AJM; de Glas NG; de Groot JWB; Haanen JBAG; Hospers GAP; van der Hoeven JJM; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Kapiteijn E; Wouters MWJM
J Geriatr Oncol; 2021 Sep; 12(7):1031-1038. PubMed ID: 34020909
[TBL] [Abstract][Full Text] [Related]
18. Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer.
Rossi AJ; Khan TM; Hong H; Lesinski GB; Wu C; Hernandez JM
Ann Surg Oncol; 2021 Aug; 28(8):4098-4099. PubMed ID: 33987757
[No Abstract] [Full Text] [Related]
19. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
20. Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Ryoo BY; Cheng AL; Ren Z; Kim TY; Pan H; Rau KM; Choi HJ; Park JW; Kim JH; Yen CJ; Lim HY; Zhou D; Straub J; Scheele J; Berghoff K; Qin S
Br J Cancer; 2021 Jul; 125(2):200-208. PubMed ID: 33972742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
